These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18827613)

  • 1. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
    Miller AA; Wang XF; Gu L; Hoffman P; Khatri J; Dunphy F; Edelman MJ; Bolger M; Vokes EE; Green MR;
    J Thorac Oncol; 2008 Oct; 3(10):1159-65. PubMed ID: 18827613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
    Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
    J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
    William WN; Zinner RG; Karp DD; Oh YW; Glisson BS; Phan SC; Stewart DJ
    J Thorac Oncol; 2007 Aug; 2(8):745-50. PubMed ID: 17762342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
    Riedel RF; Andrews C; Garst J; Dunphy F; Herndon JE; Blackwell S; Barbour S; Crawford J
    J Thorac Oncol; 2007 Jun; 2(6):520-5. PubMed ID: 17545847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
    Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
    J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
    Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
    J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
    Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
    Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
    Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
    Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
    Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience.
    Weiss J; Eaby B; Stevenson J; Kucharczuk J; Cooper J; Kaiser L; Shrager J; Rengan R; Langer C; Evans T
    J Thorac Oncol; 2010 May; 5(5):667-72. PubMed ID: 20234321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
    Borghaei H; Langer CJ; Millenson M; Ruth KJ; Litwin S; Tuttle H; Seldomridge JS; Rovito M; Mintzer D; Cohen R; Treat J
    J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.
    Masuda N; Negoro S; Hausheer F; Nakagawa K; Matsui K; Kudoh S; Takeda K; Yamamoto N; Yoshimura N; Ohashi Y; Fukuoka M
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):533-42. PubMed ID: 20473611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
    Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
    J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung cancer.
    Lilenbaum R; Samuels M; Taffaro-Neskey M; Cusnir M; Pizzolato J; Blaustein A
    J Thorac Oncol; 2010 Jun; 5(6):837-40. PubMed ID: 20421820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
    Weiss GJ; Vokes EE; Bunn PA; Magree L; Rusk J; Albert D; Kelly K
    J Thorac Oncol; 2007 Oct; 2(10):933-8. PubMed ID: 17909356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
    Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
    J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.